Chief Medical Officer

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Closes $316.2 Million Public Offering

Spyre Therapeutics Launches Public Offering

Spyre Therapeutics announces pricing of $275 million public offering of common stock

Director, Clinical Pharmacology

Spyre Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel disease and other immune-mediated diseases. The Director of Clinical Pharmacology will lead clinical pharmacology efforts, integrating model-informed approaches into drug development programs to ensure efficacy and regulatory success.

Sign up with Google

Sign in with Google